| Literature DB >> 29067255 |
Dragana Drobnjak1, Inger Christine Munch2,3, Charlotte Glümer4, Kristine Færch5, Line Kessel2,6, Michael Larsen2,6, Nina C B B Veiby1.
Abstract
PURPOSE: To examine the association between retinal vessel diameters and retinopathy in participants with and without type 2 diabetes in a Danish population-based cohort.Entities:
Keywords: CRAE, central retinal artery equivalent diameter; CRVE, central retinal vein equivalent diameter; Cohort study; Diabetic retinopathy screening; ETDRS, early treatment diabetic retinopathy study; Fundus photographs; HbA1c, glycated hemoglobin; Inter99; NPDR, non-proliferative diabetic retinopathy; Retinal vessel diameter; Retinopathy
Year: 2017 PMID: 29067255 PMCID: PMC5651334 DOI: 10.1016/j.jcte.2017.03.002
Source DB: PubMed Journal: J Clin Transl Endocrinol ISSN: 2214-6237
Associations between retinal vessel diameters (CRAE and CRVE) and retinopathy.
| All participants, any retinopathy | Participants without diabetes, any retinopathy | Participants with diabetes, any retinopathy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Coefficient (µm) | 95% confidence interval | P Value | Coefficient (µm) | 95% confidence interval | P Value | Coefficient (µm) | 95% confidence interval | P Value | |
| CRAE (µm) | 4.2 | 1.1 to 7.2 | 0.007 | 2.8 | −1.1 to 6.7 | 0.159 | 6.3 | 1.0 to 11.6 | 0.020 |
| CRVE (µm) | 4.9 | 0.7 to 9.2 | 0.021 | 2.4 | −3.0 to 8.0 | 0.382 | 7.9 | 0.7 to 15.2 | 0.030 |
Retinal vessel diameters (CRAE and CRVE) were used as dependent variables and retinopathy as independent variable in multiple linear regression analyses.
Adjusted for age, gender, HbA1c concentration, systolic blood pressure, smoking, serum total and HDL cholesterol.
Association between retinal vessel diameters (CRAE and CRVE) and individual risk factors for retinopathy onset, after multiple linear regression analyses.
| Total number N = 878 | Central retinal artery equivalent diameter (CRAE), µm | ||
|---|---|---|---|
| Coefficient (µm) | 95% confidence interval | P Value | |
| Hypertension (yes/not) | −8.5 | −10.6 to −6.4 | <0.001 |
| Age | −0.3 | −0.4 to −0.1 | <0.001 |
| Smoking (yes/no) | 0.1 | 0.4 to 0.1 | 0.001 |
| HDL (mmol/L) | −3.0 | −5.5 to −0.5 | 0.016 |
| Any Retinopathy | 4.5 | 1.4 to 7.6 | 0.005 |
| Central retinal vein equivalent diameter (CRVE), µm | |||
| Smoking (yes/no) | 0.2 | 0.1 to 0.3 | <0.001 |
| HDL (mmol/L) | −6.0 | −10.4 to −3.5 | <0.001 |
| Age | −0.2 | −0.4 to −0.04 | 0.015 |
| Gender (female) | 3.1 | 0.3 to 6.0 | 0.029 |
| Any retinopathy | 4.7 | 0.7 to 9.1 | 0.022 |
The model initially included the variables: retinopathy, age, gender, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, hypertension, smoking, body mass index, diabetes mellitus and glucose regulation.
Fig. 1Flow chart of the Inter99 Eye Study population.
Clinical characteristics of the Inter99 Eye Study population.
| Total number (n = 878) | Participants without diabetes | Participants with diabetes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No retinopathy (n = 779), 89% | p value | No retinopathy (n = 622), 92% | p value | No retinopathy (n = 157), 79% | p value | |||||
| CRAE (µm) | 878 | 163.0 (16.0) | 166.0 (15.0) | 0.101 | 164.0 (15.6) | 165.0 (13.4) | 0.338 | 161.0 (16.8) | 167.0 (15.6) | 0.035 |
| CRVE (µm) | 878 | 250.4 (21.0) | 256.0 (22.3) | 0.017 | 250.4 (20.6) | 254.0 (24.0) | 0.255 | 250,3 (21.4) | 258.0 (20.3) | 0.039 |
| SBP (mmHg) | 878 | 132.4 (17.3) | 138.4 (19.1) | 0.001 | 130.5 (16.3) | 134.0 (20.2) | 0.195 | 141.3 (18.5) | 143.7 (16.7) | 0.445 |
| DBP (mmHg) | 878 | 83.8 (11.2) | 85.5 (10.8) | 0.159 | 82.7 (11.0) | 83.6 (11.0) | 0.565 | 88.4 (11.3) | 87.5 (10.2) | 0.837 |
| Age (year) | 878 | 47.5 (7.6) | 49.8 (7.2) | 0.004 | 47 (7.6) | 49 (7.5) | 0.066 | 51 (7.2) | 51.3 (6.7) | 0.641 |
| Gender (male/female), % | 878 | 48%/52% | 56%/44% | 0.098 | 47% /53% | 46%/54% | 0.847 | 56%/44% | 72%/29% | 0.072 |
| BMI (kg/m2) | 878 | 26.0 (17.8–53.4) | 28.4 (17.5–34.8) | 0.010 | 26.1 (17.7–53.4) | 27.3 (17.5–34.8) | 0.022 | 29.6 (20.1–46.2) | 29.4 (21.1–34.0) | 0.210 |
| Total cholesterol (mmol/L) | 877 | 5.7 (1.2) | 5.8 (1.1) | 0.585 | 5.8 (1.2) | 5.7 (1.5) | 0.909 | 5.9 (1.0) | 6.0 (1.1) | 0.706 |
| HDL cholesterol (mmol/L) | 878 | 1.3 (0.3) | 1.4 (0.4) | 0.326 | 1.4 (0.4) | 1.4 (0.4) | 0.467 | 1.2 (0.3) | 1.3 (0.4) | 0.214 |
| LDL cholesterol (mmol/L) | 430 | 3.6 (1.0) | 3.7 (1.0) | 0.531 | 3.6 (1.0) | 3.8 (1.1) | 0.505 | 3.6 (1.1) | 3.6 (1.0) | 0.986 |
| Fasting p-glucose (mmol/L) | 878 | 5.6 (3.0–20.9) | 6.0 (4.8–19.7) | <0.001 | 5.5 (3.0–6.9) | 5.6 (4.8–6.8) | 0.103 | 7.0 (3.9–20.9) | 7.4 (5.0–19.7) | 0.017 |
| 2-h OGTT p-glucose (mmol/L) | 858 | 6.8 (2.3–30.6) | 7.9 (3.9–25.9) | 0.033 | 6.2 (2.3–11.0) | 6.2 (3.9–10.9) | 0.676 | 12.4 (3.9–30.6) | 12.4 (4.2–25.9) | 0.713 |
| HbA1c (%) | 877 | 6.0 (0.8) | 6.4 (1.5) | 0.006 | 5.8 (0.4) | 5.8 (0.4) | 0.878 | 6.7 (1.4) | 7.2 (1.9) | 0.128 |
| Smoking (pack years) | 878 | 4.5 (0.0–112.5) | 7.5 (0.0–90.0) | 0.080 | 3.6 (0.0–76.0) | 4.6 (0.0–5.5) | 0.215 | 7.6 (0.0–112.5) | 14.0 (0.0–90.0) | 0.677 |
Values are given as means (SD) unless otherwise stated.
Values are given as medians (interquartile range).
Grading for retinopathy was available for 878 participants. Ninety-two participants were excluded because fundus photographs were ungradable.
The inclusion of a random sample of the background population made it possible to estimate the prevalence of retinopathy in the general population. We have no reason to think that the associations we found differed between the 2 ascertainment groups as test for interaction between associated variables and ascertainment group were insignificant.